Loading
Life sciences · Journal article
Strahlentherapie Und Onkologie · September 17, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Purpose The optimal boost technique following breast-conserving surgery for patients with high-risk early breast cancer remains controversial. This study compared oncologic outcomes following an intraoperative radiotherapy (IORT) boost using low-energy X‑rays with those of a conventional external beam radiotherapy (EBRT) boost in a matched-pair cohort. Methods Patients treated with breast-conserving surgery followed by either an upfront IORT boost (20 Gy prescribed to the applicator surface) or a postoperative EBRT boost (16 Gy in 8 fractions), sequentially after whole-breast radiotherapy, between 2014 and 2019 were retrospectively identified from a prospectively maintained institutional database. Whole-breast irradiation was delivered after IORT using either conventional or moderately hypofractionated schedules according to institutional practice. The primary endpoint was ipsilateral breast tumour recurrence (IBTR). Secondary endpoints included nodal recurrence, distant metastasis, overall survival (OS), and breast cancer-specific survival (BCSS). Time-to-event outcomes were estimated using the Kaplan-Meier method, whereas treatment comparisons were performed using Cox proportional hazards regression with robust sandwich variance estimates clustered by matched pair. Results Following 1:1 matching, 400 patients (200 per group) were included. After a median follow-up of 58 months, the cumulative incidence of local recurrence was 3.5% and 2.0%, respectively, with no statistically significant difference between treatment groups (HR 1.80, 95% CI 0.58–5.58; p = 0.312). Likewise, no significant differences were observed for nodal recurrence-free survival (HR 0.98, 95% CI 0.19–5.16; p = 0.980), distant metastasis-free survival (HR 0.92, 95% CI 0.38–2.23; p = 0.859), breast cancer-specific survival (HR 0.79, 95% CI 0.30–2.10; p = 0.634), or overall survival (HR 1.19, 95% CI 0.59–2.40; p = 0.636). Conclusions In this matched-pair analysis, an intraoperative low-energy X‑ray boost achieved oncologic outcomes comparable to those of a conventional postoperative EBRT boost in patients undergoing breast-conserving therapy for high-risk early breast cancer. These findings support IORT boost as an effective and well-tolerated alternative that may simplify treatment delivery without compromising long-term oncologic outcomes.